{
  "url": "https://openlegislation.uk/eu-decision-2013-652/annex/part-A/division-3",
  "json_url": "https://openlegislation.uk/eu-decision-2013-652/annex/part-A/division-3.json",
  "legislation": "eudn/2013/652",
  "legislation_title": "Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria (notified under document C(2013) 7145) (Text with EEA relevance) (2013/652/EU)",
  "legislation_url": "https://openlegislation.uk/eu-decision-2013-652",
  "path": "annex/part/A/division/3",
  "kind": "division",
  "number": "3",
  "heading": "Antimicrobials for susceptibility testing, epidemiological cut-off values and concentration ranges to be used for antimicrobial susceptibility testing of the isolates",
  "text": "The appropriate Minister must test the antimicrobials and interpret the results using the epidemiological cut-off values and the concentration ranges that are set out in Tables 1, 2 and 3, to determine the susceptibility of Salmonella spp., C. coli, C. jejuni, indicator commensal E. coli, E. faecalis and E. faecium.\nDilution methods shall be performed according to the methods described by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), accepted as the international reference method (ISO standard 20776-1:2006).\nTable 1\nPanel of antimicrobial substances to be included in AMR monitoring, EUCAST thresholds for resistance and concentration ranges to be tested in Salmonella spp. and indicator commensal E. coli (First panel)\nEUCAST epidemiological cut-off values.\nEUCAST clinical resistance breakpoints.\nData from EUCAST available for Salmonella Enteriditis, Typhimurium, Typhi and Paratyphi.\nNAnot available.\nAntimicrobial\nSpecies\nInterpretative thresholds of AMR(mg/L)\nRange of concentrations (mg/L)(No of wells in brackets)\nECOFF\nClinical breakpoint\nAmpicillin\nSalmonella\n> 8\n> 8\n1-64 (7)\nE. coli\n> 8\n> 8\nCefotaxime\nSalmonella\n> 0,5\n> 2\n0,25-4 (5)\nE. coli\n> 0,25\n> 2\nCeftazidime\nSalmonella\n> 2\n> 4\n0,5-8 (5)\nE. coli\n> 0,5\n> 4\nMeropenem\nSalmonella\n> 0,125\n> 8\n0,03-16 (10)\nE. coli\n> 0,125\n> 8\nNalidixic acid\nSalmonella\n> 16\nNA\n4-128 (6)\nE. coli\n> 16\nNA\nCiprofloxacin\nSalmonella\n> 0,064\n> 1\n0,015-8 (10)\nE. coli\n> 0,064\n> 1\nTetracycline\nSalmonella\n> 8\nNA\n2-64 (6)\nE. coli\n> 8\nNA\nColistin\nSalmonella\n> 2\n> 2\n1-16 (5)\nE. coli\n> 2\n> 2\nGentamicin\nSalmonella\n> 2\n> 4\n0,5-32 (7)\nE. coli\n> 2\n> 4\nTrimethoprim\nSalmonella\n> 2\n> 4\n0,25-32 (8)\nE. coli\n> 2\n> 4\nSulfamethoxazole\nSalmonella\nNA\nNA\n8-1 024 (8)\nE. coli\n> 64\nNA\nChloramphenicol\nSalmonella\n> 16\n> 8\n8-128 (5)\nE. coli\n> 16\n> 8\nAzithromycin\nSalmonella\nNA\nNA\n2-64 (6)\nE. coli\nNA\nNA\nTigecycline\nSalmonella\n> 1\n> 2\n0,25-8 (6)\nE. coli\n> 1\n> 2\nTable 2\nPanel of antimicrobial substances to be included in AMR monitoring, EUCAST interpretative thresholds for resistance and concentration ranges to be tested in C. jejuni and C. coli\nEUCAST epidemiological cut-off values.\nEUCAST clinical resistance breakpoints.\nAt a voluntary basis.\nNAnot available.\nAntimicrobial\nSpecies\nInterpretative thresholds of AMR(mg/L)\nRange of concentrations (mg/L)(No of wells in brackets)\nECOFF\nClinical breakpoint\nErythromycin\nC. jejuni\n> 4\n> 4\n1-128 (8)\nC. coli\n> 8\n> 8\nCiprofloxacin\nC. jejuni\n> 0,5\n> 0,5\n0,12-16 (8)\nC. coli\n> 0,5\n> 0,5\nTetracycline\nC. jejuni\n> 1\n> 2\n0,5-64 (8)\nC. coli\n> 2\n> 2\nGentamicin\nC. jejuni\n> 2\nNA\n0,12-16 (8)\nC. coli\n> 2\nNA\nNalidixic acid\nC. jejuni\n> 16\nNA\n1-64 (7)\nC. coli\n> 16\nNA\nStreptomycin\nC. jejuni\n> 4\nNA\n0,25-16 (7)\nC. coli\n> 4\nNA\nTable 3\nPanel of antimicrobial substances to be included in AMR monitoring, EUCAST thresholds for resistance and concentration ranges to be tested in E. faecalis and E. faecium\nEUCAST epidemiological cut-off values.\nEUCAST clinical resistance breakpoints.\nNAnot available.\nAntimicrobial\nSpecies\nInterpretative thresholds of AMR(mg/L)\nRange of concentrations (mg/L)(No of wells in brackets)\nECOFF\nClinical breakpoint\nGentamicin\nE. faecalis\n> 32\nNA\n8-1 024 (8)\nE. faecium\n> 32\nNA\nChloramphenicol\nE. faecalis\n> 32\nNA\n4-128 (6)\nE. faecium\n> 32\nNA\nAmpicillin\nE. faecalis\n> 4\n> 8\n0,5-64 (8)\nE. faecium\n> 4\n> 8\nVancomycin\nE. faecalis\n> 4\n> 4\n1-128 (8)\nE. faecium\n> 4\n> 4\nTeicoplanin\nE. faecalis\n> 2\n> 2\n0,5-64 (8)\nE. faecium\n> 2\n> 2\nErythromycin\nE. faecalis\n> 4\nNA\n1-128 (8)\nE. faecium\n> 4\nNA\nQuinupristin/Dalfopristin\nE. faecalis\nNA\nNA\n0,5-64 (8)\nE. faecium\n> 1\n> 4\nTetracycline\nE. faecalis\n> 4\nNA\n1-128 (8)\nE. faecium\n> 4\nNA\nTigecycline\nE. faecalis\n> 0,25\n> 0,5\n0,03-4 (8)\nE. faecium\n> 0,25\n> 0,5\nLinezolid\nE. faecalis\n> 4\n> 4\n0,5-64 (8)\nE. faecium\n> 4\n> 4\nDaptomycin\nE. faecalis\n> 4\nNA\n0,25-32 (8)\nE. faecium\n> 4\nNA\nCiprofloxacin\nE. faecalis\n> 4\nNA\n0,12-16 (8)\nE. faecium\n> 4\nNA",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Words in Annex Pt. A point 3 substituted (31.12.2020) by The Zoonotic Disease Eradication and Control (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/740), regs. 1, 11(15); 2020 c. 1, Sch. 5 para. 1(1)"
    },
    {
      "type": "footnote",
      "label": "f1",
      "text": "EUCAST epidemiological cut-off values."
    },
    {
      "type": "footnote",
      "label": "f2",
      "text": "EUCAST clinical resistance breakpoints."
    },
    {
      "type": "footnote",
      "label": "f3",
      "text": "Data from EUCAST available for Salmonella Enteriditis, Typhimurium, Typhi and Paratyphi."
    },
    {
      "type": "footnote",
      "label": "f4",
      "text": "EUCAST epidemiological cut-off values."
    },
    {
      "type": "footnote",
      "label": "f5",
      "text": "EUCAST clinical resistance breakpoints."
    },
    {
      "type": "footnote",
      "label": "f6",
      "text": "At a voluntary basis."
    },
    {
      "type": "footnote",
      "label": "f7",
      "text": "EUCAST epidemiological cut-off values."
    },
    {
      "type": "footnote",
      "label": "f8",
      "text": "EUCAST clinical resistance breakpoints."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eudn/2013/652/annex/part/A/division/3",
    "retrieved_at": "2026-11-01T15:14:58.611363+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}